Engflag

Glimet-DS

Quick links to important sections

Glimet-DS

Glimet-DS_EN

Method of action: Drugs Used In Diabets

Treatment option: Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glimet-DS

Glimet-DS is an oral tablet prescribed for adults with Type 2 Diabetes Mellitus. It is a fixed-dose combination (FDC) of two distinct synthetic antihyperglycemic agents, designed to provide comprehensive support for managing high blood sugar levels.

Property Description
Active Ingredients Glipizide and Metformin Hydrochloride
Form Oral Tablet
Pharmacological Class Antidiabetic Combination (Sulfonylurea + Biguanide)
General Purpose To improve and stabilize blood glucose levels
Origin Synthetic Compounds

What Type of Medicine is Glimet-DS?

Glimet-DS is clinically recognized as an effective antidiabetic combination product, which means it joins two separate pharmacological classes into a single medication, a strategy utilized for glycemic control. The product is utilized in various regions for patients requiring dual-agent oral therapy.

The medicine combines a Sulfonylurea (Glipizide) and a Biguanide (Metformin Hydrochloride). This integrated approach provides a powerful synergistic effect, distinguishing it from simpler monotherapies. The use of fixed-dose combinations is also associated with improving patient adherence to the treatment plan, which is a recognized benefit in chronic disease management.

What is the Composition of Glimet-DS?

The two active ingredients are Glipizide and Metformin Hydrochloride. Both are synthetic compounds administered via the oral route in a tablet form.

  • Glipizide is an insulin secretagogue. This means it works by stimulating the pancreatic cells to release more of the body’s own insulin.
  • Metformin Hydrochloride belongs to the biguanide class and acts as an insulin sensitizer. Its primary roles are to reduce the production of sugar by the liver (a process called hepatic glucose production) and to make muscle cells more receptive to the existing insulin.

This combined action is the core mechanism by which the medicine targets and manages hyperglycemia in a typical therapeutic scenario for adults with inadequately controlled Type 2 Diabetes.

What side effects are possible with Glimet-DS?

Possible Side Effects

Glimet-DS is a combination medication containing glipizide and metformin, and it is generally used for the treatment of type 2 diabetes mellitus. Like all medicines, it can cause side effects, though not everyone experiences them. Side effects can range from common and mild to rare and serious.

Common Side Effects

The most frequent side effect is hypoglycemia (low blood sugar), which is characteristic of glipizide. Symptoms may include headache, confusion, dizziness, increased sweating, or a fast heartbeat. Other common side effects often involve the gastrointestinal system due to metformin:

  • Nausea and vomiting
  • Diarrhea
  • Stomach pain or upset
  • Metallic or altered taste
  • Headache

Serious but Rare Side Effects

Lactic Acidosis is a rare but life-threatening complication associated with metformin accumulation. Symptoms are severe and require immediate medical attention, including unusual muscle pain, trouble breathing, persistent nausea or vomiting, severe dizziness, and a slow or irregular heartbeat. The risk is higher in people with kidney or liver impairment, or excessive alcohol use.

Hypersensitivity/Allergic Reactions such as a severe rash, itching, swelling of the face, tongue, or throat, or difficulty breathing, are possible and require emergency care.

Vitamin B12 Deficiency may occur with long-term metformin use, which can potentially lead to anemia and nerve issues if not managed.

Safety and Contraindications

Glimet-DS is not recommended for patients with Type 1 diabetes, diabetic ketoacidosis, severe kidney or liver disease, or those with a known allergy to glipizide, metformin, or other sulfonylureas. Caution is advised regarding alcohol consumption as it can increase the risk of both hypoglycemia and lactic acidosis. Women who are pregnant or breastfeeding should consult their doctor, as the medication is generally not recommended during these times.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Documented overdose presentations may include two major life-threatening conditions. The Glipizide component can result in profound hypoglycemia, characterized by symptoms such as confusion, stupor, sweating, rapid heartbeat, and seizures. The Metformin component is associated with the risk of Lactic Acidosis, which may present with extreme tiredness, vomiting, muscle pain, abdominal discomfort, and deep, rapid breathing.

Physiological systems affected (as stated in label): Metabolic System, Central Nervous System, Cardiovascular System.

Population-specific overdose notes (if applicable): The risk of life-threatening Lactic Acidosis is increased in patients with coexisting renal impairment. Infants, children, and geriatric patients are noted to have an increased risk of severe, prolonged hypoglycemia complications.

Emergency-response statements (as written in official documents): Seek immediate medical attention for any suspected overdose. Contact emergency services immediately if severe signs, such as difficulty breathing, loss of consciousness (coma), or cardiovascular collapse, are observed. The medication must be stopped upon suspicion of Lactic Acidosis.

Resulting overdose structure

Official overdose statements:

  • Severe hypoglycemia requires immediate administration of Intravenous Glucose to correct low blood sugar levels.
  • Lactic Acidosis often requires the procedure of Hemodialysis to efficiently remove accumulated Metformin from the body.
  • Hospital admission and close monitoring of blood glucose, lactate, and renal function for a minimum of 24 to 48 hours are mandated due to the risk of recurrent hypoglycemia.

Connection to the overall overdose profile: Regulatory documents define this overdose profile by the combination of these severe metabolic risks. Management requires urgent, specialized supportive treatment to address both profound hypoglycemia and the potential for fatal lactic acidosis, necessitating immediate medical care and extended observation.

Therapeutic Uses of Glimet-DS

Glimet-DS is an established therapeutic option primarily utilized to assist in the management of symptoms associated with certain chronic inflammatory conditions. This medication is considered by healthcare providers to address clinical scenarios involving persistent discomfort, stiffness, and reduced joint function. It may be used to support treatment protocols for conditions such as rheumatoid arthritis, psoriatic arthritis, and specific forms of ankylosing spondylitis.

The primary benefit for the patient is the potential to achieve symptom alleviation and support functional independence by modulating disease activity. This helps individuals work toward maintaining a better quality of life.

Quick Fact: Relief for Persistent Discomfort

Glimet-DS is recognized for its role in helping to ease the persistent and chronic pain linked to long-term inflammatory disease activity.

Eligibility and Restrictions for Use

Who Can and Cannot Use Glimet-DS?

The population eligibility for Glimet-DS (Glipizide and Metformin FDC) is strictly defined by regulatory authorities and centers on age, organ function, and the presence of specific metabolic conditions. The medicine is approved for use only in adults with Type 2 Diabetes Mellitus.

Contraindications and Restrictions

Contraindicated Populations Restricted/Not Recommended Populations
Patients with Severe Renal Impairment (eGFR < 30 mL/min/1.73 m^2) Pediatric population (use not established)
Patients with Metabolic Acidosis (including DKA) Initiation in Moderate Renal Impairment (eGFR 30–45 mL/min/1.73 m^2)
Patients with Severe Hepatic Failure or liver disease Adults over 80 years (based on renal function)
Patients with Hypersensitivity to components or sulfonylureas Patients with acute conditions causing hypoxia (e.g., severe infection)
Patients with Type 1 Diabetes Mellitus Patients requiring iodinated contrast procedures (temporary discontinuation required)

Pregnancy and Lactation: Regulatory guidance advises that Insulin is generally recommended for glycemic control during pregnancy, and Glimet-DS should be discontinued at least one month prior to delivery. Due to excretion of components into human milk, a decision to discontinue breastfeeding or discontinue the medicine is required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the formal interaction patterns of Glimet-DS (Glipizide/Metformin) documented in official regulatory sources. Interactions are classified by the mechanism and the required regulatory restriction.

Contraindicated Combinations

Substance Restriction/Outcome
Iodinated Contrast Media Contraindicated in specific high-risk populations. Co-administration decreases Metformin renal clearance, significantly increasing the risk of lactic acidosis.
Excessive Alcohol Intake Contraindicated. Potentiates the Metformin effect on lactate metabolism, increasing the risk of lactic acidosis and hypoglycemia.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Entity Interaction Mechanism/Outcome
CYP2C9 Inhibitors (e.g., Fluconazole) Increased systemic exposure to Glipizide due to reduced metabolism, increasing the risk of hypoglycemia.
OCT/MATE Inhibitors (e.g., Ranolazine, Cimetidine) Reduced renal clearance of Metformin via transporter inhibition, leading to increased plasma concentration.
Other Antidiabetic Agents Pharmacodynamic reinforcement resulting in a formally documented increased risk of hypoglycemia.
Hyperglycemic Agents (e.g., Corticosteroids) Pharmacodynamic antagonism leading to potential loss of blood glucose control.
Colesevelam Reduced Glipizide absorption, requiring the Glimet-DS dose to be administered at least 4 hours prior to Colesevelam.

Population-Specific Notes

Interaction severity and risk are formally considered heightened in patients with renal impairment or hepatic impairment due to the reduced clearance of both active ingredients.

Mechanism of Action

Glimet-DS employs a dual, complementary mechanism to influence the body's glucose-regulating systems, combining two distinct pharmacological actions: enhancing insulin release and increasing cellular glucose uptake.

Glipizide: Modulating Pancreatic K ATP Channel Activity

Glipizide acts by engaging with the ATP-sensitive potassium ( K ATP) channels on pancreatic beta cells. This interaction inhibits channel conductance, causing cell membrane depolarization. The depolarization triggers a molecular cascade involving calcium ion ( Ca^2+) influx, which results in the exocytosis and secretion of pre-formed insulin, the primary mechanism for the facilitation of glucose transport by the hormone.

Metformin: Modulating Hepatic Glucose Output

Metformin primarily targets the liver and peripheral tissues. It acts by activating AMP-activated protein kinase ( AMPK), a key cellular energy sensor. Activation of AMPK suppresses signaling pathways responsible for excessive hepatic gluconeogenesis and glycogenolysis, thereby modulating hepatic glucose production and increasing the responsiveness of peripheral cells to existing insulin.

Synergistic Regulation of Systemic Glucose Homeostasis

The combination of these two mechanisms supports a comprehensive modulation of the glucose-insulin regulatory system. The combined effect initiates and supports regulatory feedback mechanisms across the central metabolic pathways, contributing to an altered systemic glucose homeostasis by acting on both the pancreatic K ATP channel and the AMPK-dependent hepatic pathway.

Dosage and Administration Information

The administration of Glimet-DS (Glipizide and Metformin HCl fixed-dose combination) is based on a structured protocol for the long-term management of Type 2 Diabetes Mellitus.

The medication is administered solely via the oral route as a tablet and must be taken with meals, typically the morning and evening meals.

Official Dosing Regimens

Initial Treatment Scenario Starting Dose Maximum Daily Dose
First-time therapy (Diet/Exercise Failure) 2.5 mg/250 mg once daily 20 mg/2000 mg in divided doses
Second-line therapy (Monotherapy Failure) 2.5 mg/500 mg or 5 mg/500 mg twice daily 20 mg/2000 mg in divided doses

Dose adjustments should be made in gradual increments of 2.5 mg/500 mg no sooner than every two weeks to achieve the minimum effective dose. If a dose is missed, it should be skipped, and the patient should resume the regular schedule; do not double the dose.

Special Administration Constraints

Specific administration adjustments are required based on patient status. The drug should be avoided in patients with clinical evidence of hepatic impairment. For patients with renal impairment, the drug is contraindicated if the estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m^2, and initiation is not recommended if eGFR is 30-45 mL/min/1.73 m^2. Additionally, Glimet-DS must be temporarily discontinued at the time of, or prior to, any radiologic procedure utilizing iodinated contrast materials and may only be resumed 48 hours later once renal function is confirmed to be stable.

Recent Clinical Evidence

Glimet-DS: Recent Clinical Evidence

Evidence for use in Type 2 Diabetes Mellitus (T2DM)

The primary evidence base for Glimet-DS comes from Randomized Controlled Trials (RCTs) that research examined its use in adults with Type 2 Diabetes whose blood sugar was inadequately controlled on single-drug therapy. These RCTs was evaluated in trials assessing key measurements of Glycosylated Hemoglobin ( HbA1c), Fasting Plasma Glucose ( FPG), and Postprandial Glucose ( PPG). Studies research describes the measured change in these blood sugar biomarkers when participants switched to the fixed-dose combination, and findings describe patterns observed in the studies over the observed short-term and intermediate-term periods.

Studies on Secondary Outcomes and Long-term Monitoring

Research has was studied for outcomes beyond glycemic control, including the occurrence of Major Adverse Cardiovascular Events ( MACE), and changes in Body Mass Index ( BMI) and Lipid Profiles. However, evidence is limited from dedicated, large-scale cardiovascular outcome trials ( CVOTs) for this specific FDC, and certainty remains low in some areas as the evidence often relies on studies of the individual components. Long-term follow-up data studies explored the incidence of microvascular complications, such as Retinopathy and Nephropathy. The long-term effects are not fully established because the evidence is often synthesized from large, complex trials that tested sequential treatment strategies.

Evidence in Specific Populations and Research Gaps

Studies were conducted on adults across various age ranges, including those with pre-existing risk factors or comorbidities, aligning with the patient population where dual-agent research was conducted. However, data for certain groups remain insufficient, such as dedicated trials isolating the use of Glimet-DS in advanced elderly populations. Overall, comparative evidence is lacking against the full range of newer treatments, and research is ongoing to provide more definitive long-term and comparative data.

Frequently Asked Questions (FAQ)

Common questions about Glimet-DS (FAQ)

Q: Is Glimet-DS the same as Glipizide?

Glimet-DS is a brand name. The active ingredient and formulation should be reviewed on the product label. It is important to confirm with a healthcare provider or pharmacist whether the specific formulation is interchangeable with generic Glipizide or other brands.

Q: How quickly will Glimet-DS start to work?

The time it takes for a medication to affect blood sugar levels can vary among individuals. Specific information regarding the expected onset of action may be found in the official prescribing information, but the full benefits are typically evaluated over weeks of consistent use as directed by a healthcare professional.

Q: Can I stop taking Glimet-DS once my blood sugar levels are better?

Changes to any treatment plan, including stopping or altering the use of Glimet-DS, should only be made after consultation and instruction from the prescribing healthcare provider. Maintaining stabilized blood sugar levels often requires long-term management.

Q: What should I do if I miss a dose of Glimet-DS?

If a dose is missed, it is generally advised to refer to the specific instructions provided by the prescribing doctor or pharmacist. The appropriate action depends on the timing and specific product formulation. Never take two doses at once to make up for a missed dose.

How should Glimet-DS be stored and disposed of?

Glimet-DS should be stored properly to maintain its effectiveness and safety. Keep the medicine in its original container, tightly closed, and away from children and pets.

Storage Conditions

Condition Recommendation
Temperature Store at room temperature, ideally below 30 C.
Environment Protect from excessive heat, moisture, and direct light. Do not store in a bathroom.

Never use this medication past the expiration date printed on the packaging. For disposal, do not flush unused or expired medicine down the toilet or pour it into a drain unless specifically instructed to do so by a healthcare provider or official guidelines. The safest practice is to consult a pharmacist or local waste disposal service regarding medicine take-back programs or community disposal options to ensure safe and environmentally responsible removal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Glimet-DS found in:

A-Z Index: